Currently, two major treatment strategies have evolved in malignant melanoma patients: firstly, targeted therapy in the form of B-Raf proto-oncogene, serine/threonine kinase (BRAF) and mitogen-activated protein kinase kinase (MAP2K; MEK) inhibitors in BRAF mutated (BRAFmt) melanoma and, secondly, immunotherapy. This evidence concerns the gene MARK2 and melanoma.